-
FTC: Authorized generics reduce overall drug prices
WASHINGTON — Branded drugs sold under their generic names at a reduced price can reduce retail and wholesale drug prices, according to a new report by the Federal Trade Commission.
The FTC report found that when an authorized generic is introduced onto the market, it can lower the expected profits of the generic drug's manufacturer and, over the longer term, affect generic manufacturers' decisions to challenge patents covering branded drugs with low sales, though patent challenges by generic drug makers "remain robust."
-
Impax confirms patent challenge for generic Nuedexta
HAYWARD, Calif. — Impax Labs has hit a roadblock in its attempts to market a generic pseudobulbar affect treatment.
Impax said that Avanir Pharmaceuticals, Avanir Holding Co. and the Center for Neurologic Study filed a patent infringement suit in the U.S. District Court of Delaware in connection with Impax's attempt to market a generic version of Nuedexta capsules (dextromethorphan hydrobromide and quinidine sulfate) in the 20-mg/10-mg strength.